<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-orange ">
                        44.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=44.0 class=" progress-orange ">44.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">44%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content">Focus on improving the Generator component, as the low score on complex questions indicates it struggles with paraphrasing, which in turn affects the overall performance on the &#39;Others&#39; topic. A potential action is to enhance the Generator&#39;s training data and fine-tuning to better handle complexity in language.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"eb83e93e-978d-4953-9fa4-790291be0bf5":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p1433","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p1435","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p1442","attributes":{"factors":["Others"]}},"x_scale":{"type":"object","name":"LinearScale","id":"p1443"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p1444"},"title":{"type":"object","name":"Title","id":"p1440","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1462","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1430","attributes":{"selected":{"type":"object","name":"Selection","id":"p1431","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1432"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"AAAAAAAARkA="},"shape":[1],"dtype":"float64","order":"little"}],["metadata_values",["Others"]],["colors",["#a50026"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1463","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1464"}}},"glyph":{"type":"object","name":"HBar","id":"p1459","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1460","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1461","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1471","attributes":{"data_source":{"id":"p1430"},"view":{"type":"object","name":"CDSView","id":"p1472","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1473"}}},"glyph":{"type":"object","name":"HBar","id":"p1468","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1469","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1470","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1481","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p1475","attributes":{"selected":{"type":"object","name":"Selection","id":"p1476","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1477"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p1482","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1483"}}},"glyph":{"type":"object","name":"Line","id":"p1478","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p1479","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p1480","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1441","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p1455","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p1450","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p1451"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p1452"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1453"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1445","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1446","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1447"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1448"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1449","attributes":{"axis":{"id":"p1445"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1454","attributes":{"dimension":1,"axis":{"id":"p1450"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p1474","attributes":{"location":44.0,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p1484","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1485","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p1481"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"eb83e93e-978d-4953-9fa4-790291be0bf5","roots":{"p1433":"f9fcfcab-3404-4f4a-ae2c-d21e3b1b6847"},"root_ids":["p1433"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="f9fcfcab-3404-4f4a-ae2c-d21e3b1b6847" data-root-id="p1433" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"791622ef-16d6-4beb-9feb-a4de7dc4ff07":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p1364","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p1294","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p1247","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1256","attributes":{"start":-0.45627567172050476,"end":6.273253917694092}},"y_range":{"type":"object","name":"Range1d","id":"p1257","attributes":{"start":10.396068572998047,"end":17.321277618408203}},"x_scale":{"type":"object","name":"LinearScale","id":"p1258"},"y_scale":{"type":"object","name":"LinearScale","id":"p1259"},"title":{"type":"object","name":"Title","id":"p1254","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1287","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1244","attributes":{"selected":{"type":"object","name":"Selection","id":"p1245","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1246"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"Pdc5QHb4EUC3jVE/EWC6P2CwD0AYBkRAgf5xQK7fdEAC1FtAHepJQICeK0BBeB1Ae3H/P9TMrj8NXxdAvj/SP4El1j9nZjs/FzSBvuyh4z5GklE/"},"shape":[21],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"j05FQaCoTUH4f2FBZp5ZQavzWkG99lVBWR5bQTfyS0FnJm5BqXl8QRtrZ0HozThBLFaBQTCAeEF16XVByLtqQbuDQEEi+DxBN7JNQWWEU0HNrUlB"},"shape":[21],"dtype":"float32","order":"little"}],["topic",["Metoprolol Medication","Metoprolol Medication","Others","Metoprolol Medication","Metoprolol Medication","Metoprolol Medication","Others","Others","Metoprolol Pharmacology","Metoprolol Pharmacology","Metoprolol Medication","Metoprolol Medication","Metoprolol Pharmacology","Metoprolol Pharmacology","Metoprolol Pharmacology","Others","Others","Others","Others","Others","Others"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20]],["content",["LOPRESSOR- metoprolol tartrate tablet \\n \\nValidus Pharmaceuticals LLC\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use \\nLOPRESSOR\\n safely and\\neffectively. See full prescribing information for \\nLOPRESSOR\\n. \\n      \\n \\nLOPRESSOR\\n (metoprolol \\ntart\\nr\\nate\\n) \\nt\\nablet\\ns\\n,\\n for \\no\\nral \\nu\\nse\\n \\nInitial U.S. Approval: \\n1992\\n \\nINDICATIONS AND USAGE\\nLOPRESSOR is a beta-adrenergic blocker indicated for the treatment of:\\nHypertension, to lower blo...","CYP2D6 Inhibitors are likely to increase metoprolol concentration. (\\n7.3\\n)\\nConcomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase\\nthe risk of bradycardia. (\\n7.4\\n)\\nBeta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the\\nwithdrawal of clonidine. (\\n7.4\\n)\\nUSE IN SPECIFIC POPULATIONS\\nHepatic Impairment: Consider initiating LOPRESSOR therapy at low doses and gradually increase\\ndosage to optimize therapy, while monit...","8.6 \\n  \\nHepatic Impairment\\n8.7 \\n  \\nRenal Impairment\\n10 \\n     \\nOVERDOSAGE\\n11 \\n     \\nDESCRIPTION\\n12 \\n      \\nCLINICAL PHARMACOLOGY\\n12.1 \\n   \\nMechanism of Action\\n12.2 \\n  \\nPharmacodynamics\\n12.3 \\n  \\nPharmacokinetics\\n12.5 \\n  \\nPharmacogenomics\\n13 \\n     \\nNONCLINICAL TOXICOLOGY\\n13.1 \\n  \\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\n14 \\n     \\nCLINICAL STUDIES\\n14.1 \\n  \\nHypertension\\n14.2 \\n  \\nAngina Pectoris\\n14.3 \\n  \\nMyocardial Infarction\\n16 \\n     \\nHOW SUPPLIED/STORAGE AND HANDLING\\n17 \\n     \\nPATIENT CO...","absolute risk increase per mmHg is greater at higher blood pressures, so that even\\nmodest reductions of severe hypertension can provide substantial benefit. Relative risk\\nreduction from blood pressure reduction is similar across populations with varying\\nabsolute risk, so the absolute benefit is greater in patients who are at higher risk\\nindependent of their hypertension (for example, patients with diabetes or\\nhyperlipidemia), and such patients would be expected to benefit from more aggressive\\ntr...","been studied. If treatment is to be discontinued, reduce the dosage gradually over a\\nperiod of 1 - 2 weeks \\n[see \\nWarnings and Precautions (\\n5.1\\n)\\n].\\n2.3 \\n  \\nMyocardial Infarction\\nSee prescribing information of intravenous metoprolol for dosage instructions for\\nintravenous therapy.\\nIn patients who tolerate the full intravenous dose, initiate Lopressor tablets, 50 mg every\\n6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for\\n48 hours. In the case of intolerance, redu...","dose of LOPRESSOR \\n[see \\nDosage and Administration (\\n2\\n)].\\n \\nIt may be necessary to lower\\nthe dose of LOPRESSOR or temporarily discontinue it. Such episodes do not preclude\\nsubsequent successful titration of LOPRESSOR.\\n5.3 \\n  \\nBronchospastic Disease\\nPatients with bronchospastic disease, should in general, not receive beta-blockers,\\nincluding Lopressor. Because of its relative beta\\n cardio-selectivity, however,\\nLOPRESSOR may be used in patients with bronchospastic disease who do not respond\\nto, o...","5.\\n9\\n \\n  \\nPeripheral Vascular Disease\\nBeta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients\\nwith peripheral vascular disease.\\n6 \\n     \\nADVERSE REACTIONS\\nThe following adverse reactions are described elsewhere in labeling:\\nWorsening angina or myocardial infarction \\n[see \\nWarnings and Precautions (\\n5\\n)]\\n \\n \\nWorsening heart failure \\n[see \\nWarnings and Precautions (\\n5\\n)\\n]\\n.\\n \\nWorsening AV block \\n[see \\nContraindications (\\n4\\n)\\n]\\n.\\n6.1 \\n  \\nClinical Trials Experience\\n...","Lopressor\\nPlacebo\\nHypotension (systolic BP &lt; 90 mm\\nHg)\\n27.4%\\n23.2%\\nBradycardia (heart rate &lt;\\n40 beats/min)\\n15.9%\\n6.7%\\nSecond- or third-degree heart block\\n4.7%\\n4.7%\\nFirst-degree heart block (P-R \\u2265\\n0.26 sec)\\n5.3%\\n1.9%\\nHeart failure\\n27.5%\\n29.6%\\n6.2 \\n  \\nPost-Marketing Experience\\nThe following adverse reactions have been identified during post approval use of\\nLOPRESSOR. Because these reactions are reported voluntarily from a population of\\nuncertain size, it is not always possible to reliably estimate...","and propafenone were shown to double metoprolol concentrations. While there is no\\ninformation about moderate or weak inhibitors, these too are likely to increase\\nmetoprolol concentration. Increases in plasma concentration decrease the\\ncardioselectivity of metoprolol \\n[see Clinical Pharmacology (\\n12.3\\n)]. \\nMonitor patients\\nclosely, when the combination cannot be avoided.\\n7.\\n4\\n \\n  \\nNegative Chronotropes\\nDigitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction\\nand d...","Data\\nHuman Data\\nData from published observational studies did not demonstrate an association of major\\ncongenital malformations and use of metoprolol in pregnancy. The published literature\\nhas reported inconsistent findings of intrauterine growth retardation, preterm birth and\\nperinatal mortality with maternal use of metoprolol during pregnancy; however, these\\nstudies have methodological limitations hindering interpretation. Methodological\\nlimitations include retrospective design, concomitant use...","(range 17.0 to 158.7). The average relative infant dosage was 0.5% of the mother&#x27;s\\nweight-adjusted dosage.\\n8.\\n3 \\n \\nFemales and Males of Reproductive Potential\\nRisk Summary\\nBased on the published literature, beta-blockers (including metoprolol) may cause\\nerectile dysfunction and inhibit sperm motility. In animal fertility studies, metoprolol has\\nbeen associated with reversible adverse effects on spermatogenesis starting at oral\\ndose level of 3.5 mg/kg in rats, which would correspond to a dose of ...","Signs and Symptoms - Overdosage of LOPRESSOR may lead to severe bradycardia,\\nhypotension, and cardiogenic shock. Clinical presentation can also include:\\natrioventricular block, heart failure, bronchospasm, hypoxia, impairment of\\nconsciousness/coma, nausea and vomiting.\\nTreatment \\u2013 Consider treating the patient with intensive care. Patients with myocardial\\ninfarction or heart failure may be prone to significant hemodynamic instability. Beta-\\nblocker overdose may result in significant resistance t...","Metoprolol is a beta\\n-selective (cardioselective) adrenergic receptor blocking agent. This\\npreferential effect is not absolute, however, and at higher plasma concentrations,\\nmetoprolol also inhibits beta\\n-adrenoreceptors, chiefly located in the bronchial and\\nvascular musculature.\\nMetoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is\\ndetectable only at plasma concentrations much greater than required for beta-blockade.\\nAnimal and human experiments indicate tha...","the ratio of approximately 2.5:1.\\nThere is a linear relationship between the log of plasma levels and reduction of exercise\\nheart rate. \\nHowever, antihypertensive activity does not appear to be related to plasma\\nlevels. Because of variable plasma levels attained with a given dose and lack of a\\nconsistent relationship of antihypertensive activity to dose, selection of proper dosage\\nrequires individual titration.\\nIn several studies of patients with acute myocardial infarction, intravenous followed...","Renal\\n \\nimpairment\\n: The systemic availability and half-life of Lopressor in patients with\\nrenal failure do not differ to a clinically significant degree from those in normal subjects.\\nHepatic Impairment:\\n Since the drug is primarily eliminated by hepatic metabolism,\\nhepatic impairment may impact the pharmacokinetics of metoprolol.\\nDrug Interactions\\nMetoprolol is metabolized predominantly by CYP2D6. In healthy subjects with CYP2D6\\nextensive metabolizer phenotype, coadministration of quinidine 10...","mg in a 60-kg patient.\\n14 \\n     \\nCLINICAL STUDIES\\n14.1 \\n  \\nHypertension\\nIn controlled clinical studies, Lopressor has been shown to be an effective\\nantihypertensive agent when used alone or as concomitant therapy with thiazide-type\\ndiuretics, at dosages of 100 mg to 450 mg daily. In controlled, comparative, clinical\\nstudies, Lopressor has been shown to be as effective an antihypertensive agent as\\npropranolol, methyldopa, and thiazide-type diuretics, to be equally effective in supine and\\nstanding...","however, it is also reasonable to administer the drug orally to patients at a later time as\\nis recommended for certain other beta-blockers.\\n16 \\n     \\nHOW SUPPLIED/STORAGE AND HANDLING\\nLopressor \\n(\\nmetoprolol tartrate\\n)\\n \\nt\\nablets\\nTablets 50 mg \\n\\u2013 capsule-shaped, biconvex, pink, scored (imprinted LOPRESSOR on\\none side and 458 twice on the scored side)\\n      \\nBottles of 100\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026.\\u2026\\u2026\\u2026NDC 30698-458-01\\nTablets 100 mg \\n\\u2013 capsule-shaped, biconvex, light blue, scored (imprinted LOPRESSOR\\non on...","NDC 30698-458-01\\nLopressor\\n(metoprolol tartrate USP) Tablets\\n50 mg\\n100 Tablets\\nRx Only\\nPRINCIPAL DISPLAY PANEL\\nNDC 30698-459-01\\nLopressor\\n(metoprolol tartrate USP) Tablets\\n100 mg\\n100 Tablets\\nRx Only\\nLOPRESSOR  \\nmetoprolol tartrate tablet\\nProduct Information","Product Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:30698-458\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nMETOPROLOL TARTRATE\\n (UNII: W5S57Y3A5L) \\n(METOPROLOL -\\nUNII:GEB06NHM23)\\nMETOPROLOL\\nTARTRATE\\n50 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nD&amp;C RED NO. 30\\n (UNII: 2S42T2808B)\\n \\nLACTOSE, UNSPECIFIED FORM\\n (UNII: J2B2A4N98G)\\n \\nMAGNESIUM...","Product Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:30698-459\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nMETOPROLOL TARTRATE\\n (UNII: W5S57Y3A5L) \\n(METOPROLOL -\\nUNII:GEB06NHM23)\\nMETOPROLOL\\nTARTRATE\\n100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nFD&amp;C BLUE NO. 2\\n (UNII: L06K8R7DQK)\\n \\nLACTOSE, UNSPECIFIED FORM\\n (UNII: J...","Validus Pharmaceuticals LLC\\n \\nRevised: 9/2023"]],["color",{"type":"ndarray","array":["#1f77b4","#1f77b4","#999","#1f77b4","#1f77b4","#1f77b4","#999","#999","#aec7e8","#aec7e8","#1f77b4","#1f77b4","#aec7e8","#aec7e8","#aec7e8","#999","#999","#999","#999","#999","#999"],"shape":[21],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1288","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1289"}}},"glyph":{"type":"object","name":"Scatter","id":"p1284","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1285","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1286","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1255","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p1270","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p1271"},{"type":"object","name":"WheelZoomTool","id":"p1272","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1273","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1274","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1279"},{"type":"object","name":"SaveTool","id":"p1280"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1265","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1266","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1267"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1268"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1260","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1261","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1262"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1263"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1264","attributes":{"axis":{"id":"p1260"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1269","attributes":{"dimension":1,"axis":{"id":"p1265"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1290","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1291","attributes":{"label":{"type":"value","value":"Metoprolol Medication"},"renderers":[{"id":"p1287"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1292","attributes":{"label":{"type":"value","value":"Metoprolol Pharmacology"},"renderers":[{"id":"p1287"}],"index":8}},{"type":"object","name":"LegendItem","id":"p1293","attributes":{"label":{"type":"value","value":"Others"},"renderers":[{"id":"p1287"}],"index":2}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p1363","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p1299","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1308","attributes":{"start":-0.45627567172050476,"end":6.273253917694092}},"y_range":{"type":"object","name":"Range1d","id":"p1309","attributes":{"start":10.396068572998047,"end":17.321277618408203}},"x_scale":{"type":"object","name":"LinearScale","id":"p1310"},"y_scale":{"type":"object","name":"LinearScale","id":"p1311"},"title":{"type":"object","name":"Title","id":"p1306","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1338","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1295","attributes":{"selected":{"type":"object","name":"Selection","id":"p1296","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1297"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"FzSBvmCwD0Cu33RA7KHjPj3XOUAYBkRAZ2Y7P3b4EUBGklE/DV8XQBFguj+BJdY/HepJQICeK0CB/nFAvj/SPwLUW0BBeB1At41RP3tx/z/UzK4/GAZEQNTMrj+u33RAgf5xQA=="},"shape":[25],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"N7JNQavzWkE38ktBZYRTQY9ORUG99lVBIvg8QaCoTUHNrUlBdel1QWaeWUG7g0BBqXl8QRtrZ0FZHltByLtqQWcmbkHozThB+H9hQSxWgUEwgHhBvfZVQTCAeEE38ktBWR5bQQ=="},"shape":[25],"dtype":"float32","order":"little"}],["topic",["Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others","Others"]],["correctness",[false,false,false,false,true,false,true,true,false,true,false,false,true,false,true,false,true,false,false,true,true,false,true,false,true]],["questions",["Considering the information provided about the 50 mg Metoprolol Tartrate tablets, what is the exact marketing start date, and ensure you differentiate it from the 100 mg variant?","Under what specific medical conditions or circumstances should Lopressor not be used, and are there any exceptions to these contraindications, such as in cases where a permanent pacemaker is present?","Could you detail some central nervous system adverse reactions linked to Lopressor that have been identified during post-marketing, considering these reports are voluntary and from an uncertain population size?","What is the exact dosage strength of the active ingredient found in the light blue capsule form of Lopressor, considering the product characteristics and inactive ingredients listed in the provided context?","Considering the contraindications listed for LOPRESSOR, under what specific medical conditions or patient characteristics should this medication be avoided, particularly focusing on cardiovascular-related issues?","When administering LOPRESSOR to individuals with bronchospastic conditions, what considerations must be taken into account, especially if they have not responded to other antihypertensive treatments and require the lowest possible dose?","Considering the information on the packaging, what is the primary active chemical compound found in Lopressor tablets, and does it differ between the 50 mg and 100 mg versions?","When starting LOPRESSOR treatment in patients with hepatic impairment, what specific precautions and dosage adjustments should be taken into account, considering the potential for adverse reactions and the need for careful monitoring?","Could you tell me the exact month and year when the details from Validus Pharmaceuticals LLC were most recently updated, according to the latest document revision?","How does the presence of hepatic impairment alter the pharmacokinetics of metoprolol, considering that it is primarily metabolized by the liver, and what implications might this have for patients with liver conditions?","Considering the need for individualizing treatment, what is the advised starting dose of Lopressor for managing hypertension, and are there any specific conditions under which this dosage should be adjusted?","Under what specific conditions, including temperature range and protective measures, should Lopressor tablets be stored to ensure their efficacy and safety?","Considering the methodological limitations of the studies, what are the reported risks, if any, of using metoprolol during pregnancy, and how do these limitations affect the interpretation of the risks like intrauterine growth retardation or preterm birth?","According to animal studies, what are the specific effects of metoprolol on fertility, particularly focusing on any reversible adverse effects on spermatogenesis and the conditions under which these effects were observed?","Considering the information provided about beta-blockers, what specific adverse reactions should be anticipated in patients already diagnosed with peripheral vascular disease, especially regarding arterial insufficiency and other cardiovascular issues?","In the clinical study involving myocardial infarction patients, what was the impact of Lopressor, considering the timing of administration and any observed changes in mortality or symptoms, while also taking into account any exclusion criteria for patient participation?","Considering the use of metoprolol in pregnant women, what are the specific health risks that neonates might face immediately after birth, and how should these conditions be managed, taking into account the potential for hypotension, hypoglycemia, bradycardia, and respiratory depression?","Under what specific circumstances or conditions might the signs and symptoms of an overdose of LOPRESSOR, such as severe bradycardia, hypotension, or cardiogenic shock, become more pronounced or severe?","Under what specific conditions is LOPRESSOR prescribed for adult patients, considering its role in managing cardiovascular health and any associated risks or benefits?","According to clinical pharmacology studies, how does metoprolol affect heart rate and cardiac output, and are there any specific conditions or plasma concentrations that alter these effects?","Under normal physiological conditions, considering factors like pre-systemic metabolism, what is the estimated percentage of immediate release metoprolol that becomes bioavailable after oral administration?","When administering LOPRESSOR to patients diagnosed with pheochromocytoma, what specific precautions must be taken, particularly regarding the combination with other medications, and why is this combination necessary?","Considering the effect of pre-systemic metabolism on drug absorption, what is the approximate percentage of immediate release metoprolol that is bioavailable when taken orally, and how does this saturation impact the dose-exposure relationship?","Could you detail some of the adverse reactions related to the central nervous system that have been observed during the post-marketing phase of Lopressor, and include any conditions about their reversibility or progression?","Considering patients with both hypertension and angina, what are some of the more frequently observed adverse reactions to beta-blockers, particularly focusing on those affecting the central nervous system and cardiovascular system?"]],["agent_answer",["The exact marketing start date for the 50 mg Metoprolol Tartrate tablets is not provided in the given information. However, it is important to note that the marketing start date for the 50 mg variant may differ from the marketing start date for the 100 mg variant of Metoprolol Tartrate tablets. It is recommended to refer to official sources or contact the manufacturer for the specific marketing start date of the 50 mg variant.","Lopressor (metoprolol) should not be used in patients with certain medical conditions or circumstances, including:\\n\\n1. Bradycardia (slow heart rate)\\n2. Hypotension (low blood pressure)\\n3. Heart block greater than first degree\\n4. Cardiogenic shock\\n5. Severe peripheral arterial circulatory disorders\\n6. Untreated phaeochromocytoma (a rare adrenal gland tumor)\\n\\nThere may be exceptions to these contraindications in certain cases, such as when a patient with a permanent pacemaker requires treatment with Lopressor. In such cases, the benefits of using Lopressor may outweigh the risks associated with the contraindications. It is important for a healthcare provider to carefully assess the individual patient&#x27;s situation and medical history before deciding whether Lopressor can be safely used.","Yes, some central nervous system adverse reactions linked to Lopressor that have been identified during post-marketing include dizziness, headache, fatigue, and confusion. These reports are voluntary and come from an uncertain population size, so it is important to note that the frequency and severity of these reactions may not be accurately represented. It is always recommended to consult with a healthcare professional if you experience any concerning side effects while taking Lopressor.","The exact dosage strength of the active ingredient found in the light blue capsule form of Lopressor is likely 50 mg based on the information provided in the context of the product characteristics and inactive ingredients.","LOPRESSOR (metoprolol) should be avoided in patients with certain cardiovascular conditions, including:\\n\\n1. Heart block greater than first degree: LOPRESSOR can worsen heart block in patients with pre-existing conduction abnormalities.\\n\\n2. Sinus bradycardia: LOPRESSOR can further slow down the heart rate in patients with already low heart rates.\\n\\n3. Cardiogenic shock: LOPRESSOR should be avoided in patients with cardiogenic shock, as it can further decrease cardiac output.\\n\\n4. Decompensated heart failure: LOPRESSOR is contraindicated in patients with decompensated heart failure, as it can worsen symptoms of heart failure.\\n\\n5. Severe peripheral arterial circulatory disorders: LOPRESSOR should be used with caution in patients with severe peripheral arterial circulatory disorders, as it can worsen peripheral vascular resistance.\\n\\n6. Hypotension: LOPRESSOR can cause further decrease in blood pressure, so caution should be exercised in patients with low blood pressure.\\n\\nIn general, LOPRESSOR should be used with caution in patients with underlying cardiovascular conditions and careful monitoring is required to ensure safe and effective use of the medication.","When administering LOPRESSOR to individuals with bronchospastic conditions who have not responded to other antihypertensive treatments and require the lowest possible dose, several considerations must be taken into account:\\n\\n1. LOPRESSOR (metoprolol) is a beta-blocker, and beta-blockers can potentially exacerbate bronchospasm in individuals with bronchospastic conditions. Therefore, careful monitoring for any signs of worsening respiratory symptoms should be carried out, and alternative medications may need to be considered in some cases.\\n\\n2. The lowest possible dose of LOPRESSOR should be prescribed to minimize the risk of exacerbating bronchospasm. This may involve starting at a very low dose and titrating upwards slowly while closely monitoring the individual&#x27;s respiratory function.\\n\\n3. Close communication between the healthcare provider and the individual with bronchospastic conditions is crucial. The individual should be educated about the potential risks and benefits of LOPRESSOR treatment, as well as the importance of reporting any changes in respiratory symptoms promptly.\\n\\n4. In some cases, a combination of medications may be necessary to effectively manage both hypertension and bronchospastic conditions. The healthcare provider should carefully consider the potential interactions between LOPRESSOR and other medications being taken by the individual.\\n\\nOverall, when administering LOPRESSOR to individuals with bronchospastic conditions who have not responded to other antihypertensive treatments and require the lowest possible dose, careful monitoring, education, and communication are key to ensuring the safety and effectiveness of the treatment.","The primary active chemical compound found in Lopressor tablets is metoprolol tartrate. This compound does not differ between the 50 mg and 100 mg versions of the medication, as both strengths contain metoprolol tartrate as their active ingredient.","When starting LOPRESSOR treatment in patients with hepatic impairment, specific precautions and dosage adjustments should be taken into account to minimize the potential for adverse reactions and ensure careful monitoring of the patient&#x27;s response to the medication. \\n\\nFirstly, it is important to consider that LOPRESSOR is primarily metabolized by the liver, so patients with hepatic impairment may have reduced metabolism of the drug, leading to higher levels of the medication in their system and an increased risk of adverse reactions.\\n\\nTo address this, dosage adjustments may be necessary in patients with hepatic impairment. The initial dose of LOPRESSOR should be reduced, and the dose should be titrated slowly based on the patient&#x27;s response and tolerability. Close monitoring of blood pressure, heart rate, and other relevant clinical parameters is essential to ensure that the patient is responding appropriately to the medication.\\n\\nAdditionally, patients with hepatic impairment may be at higher risk of experiencing certain adverse reactions associated with LOPRESSOR, such as bradycardia (slow heart rate) or hypotension (low blood pressure). Monitoring for signs and symptoms of these adverse reactions is important, and dose adjustments may be needed if they occur.\\n\\nOverall, when initiating LOPRESSOR treatment in patients with hepatic impairment, healthcare providers should carefully consider the patient&#x27;s liver function, adjust the dosage as needed, and closely monitor the patient for any potential adverse reactions to ensure safe and effective use of the medication.","I&#x27;m sorry, but as an AI, I don&#x27;t have access to real-time data or the ability to browse the internet to find the specific information about Validus Pharmaceuticals LLC. You may need to check their official website or contact the company directly for the most up-to-date information on their document revision dates.","The presence of hepatic impairment can significantly alter the pharmacokinetics of metoprolol, as it is primarily metabolized by the liver. In patients with hepatic impairment, the clearance of metoprolol can be reduced, leading to higher plasma concentrations and prolonged elimination half-life.\\n\\nThis may lead to an increased risk of adverse effects such as bradycardia, hypotension, and increased risk of adverse effects on liver function. In patients with severe hepatic impairment, the use of metoprolol may be contraindicated due to the potential for significant accumulation of the drug.\\n\\nFor patients with liver conditions, it is important to closely monitor the plasma levels of metoprolol and adjust the dosage accordingly to avoid toxicity. It may also be necessary to consider alternative treatment options that are not primarily metabolized by the liver in patients with severe hepatic impairment. Overall, the presence of hepatic impairment can have significant implications for the use of metoprolol in patients with liver conditions, and careful monitoring and dose adjustments are essential to ensure safe and effective treatment.","The advised starting dose of Lopressor (Metoprolol) for managing hypertension is typically 50 mg twice daily. However, this dose may vary depending on the individual patient&#x27;s age, weight, renal function, and other medical conditions.\\n\\nIn specific conditions such as renal impairment, hepatic impairment, or concurrent use of certain medications, the starting dose of Lopressor may need to be adjusted. Patients with severe renal impairment may require a lower initial dose, while those with hepatic impairment may need a reduced dose due to the drug&#x27;s metabolism being affected.\\n\\nIt is important to consult with a healthcare provider or a doctor to determine the appropriate starting dose and any necessary adjustments based on the individual&#x27;s specific medical history and conditions.","Lopressor tablets should be stored at room temperature between 68\\u00b0F to 77\\u00b0F (20\\u00b0C to 25\\u00b0C). They should be kept in a dry place away from moisture and direct sunlight. It is important to store Lopressor tablets in their original packaging to protect them from light and moisture. Additionally, they should be kept out of reach of children and pets.\\n\\nIt is important to follow these storage conditions to ensure the efficacy and safety of Lopressor tablets. Storing them in an improper environment could degrade the medication and reduce its effectiveness.","Some reported risks of using metoprolol during pregnancy include intrauterine growth retardation and preterm birth. However, the methodological limitations of the studies, such as small sample sizes, retrospective designs, and confounding variables, affect the interpretation of these risks. \\n\\nFor example, small sample sizes may not be representative of the general population, leading to a potential bias in the results. Retrospective study designs may rely on self-reported data or medical records, which can introduce inaccuracies. Confounding variables, such as maternal health conditions or other medications taken during pregnancy, can also impact the results and make it difficult to isolate the effects of metoprolol alone.\\n\\nTherefore, it is important to consider these limitations when interpreting the reported risks of using metoprolol during pregnancy. Additional large-scale, well-designed studies are needed to provide more definitive conclusions on the potential risks associated with metoprolol use in pregnancy.","Animal studies have shown that metoprolol, a beta-blocker medication commonly used to treat high blood pressure and heart conditions, can have adverse effects on fertility, specifically on spermatogenesis in males. These effects include reduced sperm count, motility, and viability, as well as altered sperm morphology.\\n\\nHowever, it is important to note that these effects are reversible and sperm parameters return to normal once metoprolol treatment is discontinued. These adverse effects on spermatogenesis have been observed in animal studies at high doses of metoprolol, usually exceeding the therapeutic dose used in humans. \\n\\nOverall, while metoprolol may have temporary effects on fertility in males, these effects are reversible and can be avoided by using the medication at appropriate therapeutic doses. It is important for individuals considering metoprolol treatment to consult with their healthcare provider to discuss any potential concerns about fertility.","Patients with peripheral vascular disease who are prescribed beta-blockers may experience specific adverse reactions related to their condition, such as worsening of arterial insufficiency symptoms. Beta-blockers can cause vasoconstriction (narrowing of blood vessels), which can further reduce blood flow to the extremities in patients with peripheral vascular disease, leading to increased pain, cramping, and potential worsening of ulcerations or gangrene.\\n\\nAdditionally, beta-blockers can also affect the heart rate and blood pressure, which may be concerning for patients with cardiovascular issues. Some specific adverse reactions in this population may include increased risk of heart failure exacerbation, worsening of symptoms related to coronary artery disease, and potentially dangerous drops in blood pressure.\\n\\nTherefore, healthcare providers should closely monitor patients with peripheral vascular disease who are taking beta-blockers for any signs of worsening arterial insufficiency, cardiovascular symptoms, or other adverse reactions. Adjustments to the medication regimen or alternative treatment options may be necessary to ensure the patient&#x27;s safety and well-being.","In the clinical study involving myocardial infarction patients, the impact of Lopressor (metoprolol) was found to be beneficial when administered within the first 24 hours of symptom onset. Patients who received Lopressor within this time frame had a lower risk of mortality compared to those who did not receive the medication. Additionally, patients who received Lopressor showed improvement in symptoms such as chest pain and shortness of breath.\\n\\nIt is important to note that there were exclusion criteria for patient participation in the study, such as patients with certain pre-existing medical conditions or contraindications to beta-blocker therapy. These criteria were put in place to ensure the safety and efficacy of the medication in the study population.\\n\\nOverall, the study showed that the timing of Lopressor administration in myocardial infarction patients plays a crucial role in improving outcomes and reducing mortality, while also considering exclusion criteria for patient participation to ensure the medication&#x27;s safety and effectiveness in the study population.","Metoprolol is a medication commonly used to treat high blood pressure and other cardiovascular conditions. When used in pregnant women, there are specific health risks that neonates might face immediately after birth due to exposure to the drug. These risks include hypotension (low blood pressure), hypoglycemia (low blood sugar), bradycardia (slow heart rate), and respiratory depression.\\n\\nIn the case of hypotension, neonates may present with symptoms such as lethargy, poor feeding, and weak pulse. To manage this condition, neonates may require fluids and in severe cases, vasopressors to help increase blood pressure.\\n\\nHypoglycemia can result in neonates having jitteriness, poor feeding, and seizures. The mainstay of treatment for hypoglycemia is to provide glucose either orally or intravenously to raise blood sugar levels.\\n\\nBradycardia, or a slow heart rate, can cause neonates to have symptoms such as poor feeding and pale skin. In severe cases, neonates may require cardiac monitoring and potentially the use of medications such as atropine to increase heart rate.\\n\\nRespiratory depression may cause neonates to have difficulty breathing, apnea, and poor oxygen saturation. Neonates with respiratory depression may require respiratory support such as oxygen therapy or mechanical ventilation.\\n\\nWhen managing these conditions in neonates exposed to metoprolol in utero, it is important to closely monitor their vital signs, blood sugar levels, and overall clinical status. Individualized treatment plans should be developed based on the severity of the symptoms and the neonate&#x27;s response to interventions. Additionally, healthcare providers should slowly wean the neonate off of any medications used for treatment to avoid rebound effects. Consulting with neonatal specialists and pharmacists is advisable to ensure the best care for neonates exposed to metoprolol.","The signs and symptoms of an overdose of LOPRESSOR, such as severe bradycardia, hypotension, or cardiogenic shock, may become more pronounced or severe under specific circumstances or conditions such as:\\n\\n1. Excessive ingestion of LOPRESSOR: Taking a higher dose of LOPRESSOR than prescribed or intentionally overdosing on the medication can lead to a more severe overdose and intensified symptoms.\\n\\n2. Co-ingestion with other medications: Taking LOPRESSOR with other medications that affect heart rate or blood pressure can amplify the effects of the drug and lead to more severe symptoms of overdose.\\n\\n3. Pre-existing heart conditions: Individuals with pre-existing heart conditions such as heart failure or conduction abnormalities may be more susceptible to severe bradycardia, hypotension, or cardiogenic shock in cases of LOPRESSOR overdose.\\n\\n4. Impaired liver or kidney function: Patients with impaired liver or kidney function may have a reduced ability to metabolize and excrete LOPRESSOR, leading to higher levels of the drug in the body and an increased risk of overdose symptoms.\\n\\n5. Prolonged QT interval: LOPRESSOR can prolong the QT interval in some individuals, and co-existing factors that further prolong the QT interval, such as electrolyte imbalances or certain medications, can increase the risk of severe cardiac complications in cases of overdose. \\n\\nIt is important to seek medical attention immediately if an overdose of LOPRESSOR is suspected, as prompt intervention is crucial in managing and minimizing the potential complications of overdose.","LOPRESSOR, also known as metoprolol, is typically prescribed for adult patients under the following specific conditions:\\n\\n- Hypertension: LOPRESSOR may be prescribed to lower high blood pressure and reduce the risk of heart attack and stroke.\\n- Angina: LOPRESSOR can be used to treat chest pain or discomfort caused by reduced blood flow to the heart muscle.\\n- Heart failure: LOPRESSOR may be prescribed to improve symptoms and reduce the risk of hospitalization in patients with heart failure.\\n- Myocardial infarction (heart attack): LOPRESSOR may be given to improve survival and reduce the risk of future heart attacks in patients who have had a heart attack.\\n\\nIt is important for patients to discuss with their healthcare provider the potential benefits and risks of taking LOPRESSOR, as it can have side effects such as low blood pressure, dizziness, fatigue, and breathing problems. Patients with certain medical conditions, such as asthma or diabetes, may need to be monitored closely while taking LOPRESSOR.","Metoprolol is a beta-blocker medication that works by reducing the stimulatory effects of adrenaline on the heart. This results in a decrease in heart rate and cardiac output. \\n\\nClinical pharmacology studies have shown that metoprolol reduces heart rate by blocking beta-1 adrenergic receptors in the heart, leading to a decrease in the heart&#x27;s ability to beat faster in response to stress or exercise. This reduction in heart rate helps to decrease the oxygen demand of the heart, making it beneficial in conditions like angina or heart failure.\\n\\nMetoprolol has also been shown to decrease cardiac output by reducing the force of contraction of the heart muscle. This can be particularly beneficial in conditions like hypertension or certain types of arrhythmias where reducing the workload of the heart can be helpful.\\n\\nIt is important to note that the effects of metoprolol on heart rate and cardiac output can be influenced by factors such as the individual&#x27;s age, underlying heart conditions, and plasma concentrations of the medication. Higher plasma concentrations of metoprolol can lead to a more pronounced decrease in heart rate and cardiac output. Additionally, certain conditions such as liver or kidney disease can affect the metabolism and clearance of metoprolol, potentially altering its effects on the cardiovascular system. Overall, it is important for healthcare providers to carefully monitor patients on metoprolol and adjust dosages as needed to achieve the desired therapeutic effects.","Approximately 50% of immediate release metoprolol becomes bioavailable after oral administration, taking into account factors like pre-systemic metabolism.","When administering LOPRESSOR to patients diagnosed with pheochromocytoma, specific precautions must be taken in terms of the combination with other medications. It is important to avoid using LOPRESSOR alongside other alpha-blocking agents, as this can result in a potentially dangerous hypotensive response. This combination can lead to a sudden drop in blood pressure, which can be life-threatening in individuals with pheochromocytoma.\\n\\nInstead, LOPRESSOR is often combined with an alpha-blocking agent, such as phenoxybenzamine, prior to surgical removal of the tumor. This combination helps to control the blood pressure and reduce the risk of a sudden hypertensive crisis during surgery. By blocking both alpha and beta adrenergic receptors, LOPRESSOR helps to manage the symptoms of pheochromocytoma, such as hypertension, palpitations, and sweating.\\n\\nIn summary, when administering LOPRESSOR to patients with pheochromocytoma, precautions must be taken to avoid combining it with other alpha-blocking agents to prevent a dangerous drop in blood pressure. Instead, LOPRESSOR is commonly used in conjunction with an alpha-blocking agent to manage symptoms and prepare for surgery.","The approximate percentage of immediate release metoprolol that is bioavailable when taken orally is around 50%. This means that only half of the drug that is ingested actually reaches the systemic circulation.\\n\\nThe saturation of pre-systemic metabolism can impact the dose-exposure relationship by leading to non-linear pharmacokinetics. As the dose of metoprolol increases, the amount of drug that bypasses pre-systemic metabolism remains the same, resulting in a disproportionate increase in drug exposure. This can lead to an increased risk of side effects or toxicity at higher doses. Additionally, variations in pre-systemic metabolism between individuals can lead to variability in drug absorption and bioavailability, further complicating the dose-exposure relationship.","Some adverse reactions related to the central nervous system that have been observed during the post-marketing phase of Lopressor (metoprolol) include:\\n\\n1. Dizziness or lightheadedness: Patients may experience a feeling of spinning or instability, which can be caused by a sudden drop in blood pressure.\\n\\n2. Fatigue or drowsiness: Some individuals may feel unusually tired or sleepy while taking Lopressor, which can affect their daily activities.\\n\\n3. Headache: Headaches may occur as a side effect of metoprolol, ranging from mild discomfort to severe pain.\\n\\n4. Memory problems or confusion: Some patients may experience difficulty concentrating, remembering things, or feeling confused while taking Lopressor.\\n\\n5. Depression or mood changes: Changes in mood, such as sadness, irritability, or anxiety, have been reported as possible side effects of metoprolol.\\n\\nThese adverse reactions are typically reversible upon discontinuation of Lopressor or through dose adjustments. However, in some cases, these symptoms may persist or worsen over time, requiring further medical evaluation and management. It is important for patients to report any concerning side effects to their healthcare provider for appropriate assessment and treatment.","Some of the more frequently observed adverse reactions to beta-blockers in patients with hypertension and angina, particularly affecting the central nervous system, include dizziness, fatigue, and weakness. These side effects may be more pronounced in elderly patients or those with preexisting central nervous system conditions.\\n\\nIn terms of the cardiovascular system, common adverse reactions to beta-blockers in this patient population may include bradycardia (slow heart rate), hypotension (low blood pressure), and exacerbation of heart failure symptoms. Patients may also experience symptoms such as shortness of breath, chest pain, and palpitations.\\n\\nIt is important for healthcare providers to monitor patients carefully for these adverse reactions when initiating beta-blocker therapy, and to adjust the dose or consider alternative treatments if necessary to minimize the risk of complications."]],["reference_answer",["05/05/2014","Lopressor is contraindicated in severe bradycardia, second- or third-degree heart block, cardiogenic shock, systolic blood pressure &lt;100, decompensated heart failure, sick sinus syndrome (unless a permanent pacemaker is in place), and in patients who are hypersensitive to any component of this product.","Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.","The strength of the active ingredient, Metoprolol Tartrate, in the blue capsule form of Lopressor is 100 mg.","Known hypersensitivity to product components, severe bradycardia, greater than first degree heart block, sick sinus syndrome without a pacemaker, cardiogenic shock, or decompensated heart failure.","Patients with bronchospastic disease should in general not receive beta-blockers, including Lopressor. However, due to its relative beta cardio-selectivity, LOPRESSOR may be used in patients who do not respond to, or cannot tolerate, other antihypertensive treatment. The lowest possible dose of LOPRESSOR should be used, and bronchodilators, including beta-agonists, should be readily available or administered concomitantly.","The active ingredient in Lopressor tablets is metoprolol tartrate USP.","Consider initiating LOPRESSOR therapy at low doses and gradually increase dosage to optimize therapy, while monitoring closely for adverse events.","September 2023","Since the drug is primarily eliminated by hepatic metabolism, hepatic impairment may impact the pharmacokinetics of metoprolol.","The usual initial dosage is 100 mg daily in single or divided doses.","Store at 77\\u00b0F (25\\u00b0C); excursions permitted to 59\\u00b0 to 86\\u00b0F (15\\u00b0 to 30\\u00b0C). Protect from moisture and heat. Dispense in a tight, light-resistant container (USP).","The published literature has reported inconsistent findings of intrauterine growth retardation, preterm birth, and perinatal mortality with maternal use of metoprolol during pregnancy; however, these studies have methodological limitations hindering interpretation.","In animal fertility studies, metoprolol has been associated with reversible adverse effects on spermatogenesis starting at an oral dose level of 3.5 mg/kg in rats, which would correspond to a dose of 34 mg/day in humans in mg/m equivalent, although other studies have shown no effect of metoprolol on reproductive performance in male rats.","Beta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease.","In a large, double-blind, placebo-controlled clinical study, Lopressor was shown to reduce 3-month mortality by 36% in patients with suspected or definite myocardial infarction.","Neonates born to mothers who are receiving metoprolol during pregnancy may be at risk for hypotension, hypoglycemia, bradycardia, and respiratory depression.","Overdosage of LOPRESSOR may lead to severe bradycardia, hypotension, and cardiogenic shock. Clinical presentation can also include atrioventricular block, heart failure, bronchospasm, hypoxia, impairment of consciousness/coma, nausea, and vomiting.","LOPRESSOR is indicated for the treatment of hypertension in adult patients, to lower blood pressure.","Clinical pharmacology studies have confirmed that metoprolol reduces heart rate and cardiac output at rest and upon exercise.","The estimated oral bioavailability of immediate release metoprolol is about 50% because of pre-systemic metabolism.","If LOPRESSOR is used in the setting of pheochromocytoma, it should be given in combination with an alpha blocker, and only after the alpha blocker has been initiated. Administration of beta-blockers alone in the setting of pheochromocytoma has been associated with a paradoxical increase in blood pressure due to the attenuation of beta-mediated vasodilatation in skeletal muscle.","The estimated oral bioavailability of immediate release metoprolol is about 50% because of pre-systemic metabolism.","Reversible mental depression progressing to catatonia; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics.","Common adverse reactions include tiredness and dizziness in about 10% of patients, depression in about 5% of patients, shortness of breath and bradycardia in approximately 3% of patients, and diarrhea in about 5% of patients. Other reported reactions are mental confusion, short-term memory loss, headache, nightmares, insomnia, cold extremities, palpitations, heart failure exacerbations, peripheral edema, hypotension, wheezing, dyspnea, rhinitis, nausea, dry mouth, gastric pain, constipation, flatulence, heartburn, pruritus, rash, photosensitivity, worsening of psoriasis, Peyronie\\u2019s disease, musculoskeletal pain, blurred vision, and tinnitus."]],["id",[18,4,7,19,0,5,17,1,20,14,3,16,9,10,6,15,8,11,2,12,13,5,13,7,6]],["content",["Product Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:30698-458\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nMETOPROLOL TARTRATE\\n (UNII: W5S57Y3A5L) \\n(METOPROLOL -\\nUNII:GEB06NHM23)\\nMETOPROLOL\\nTARTRATE\\n50 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nD&amp;C RED NO. 30\\n (UNII: 2S42T2808B)\\n \\nLACTOSE, UNSPECIFIED FORM\\n (UNII: J2B2A4N98G)\\n \\nMAGNESIUM...","been studied. If treatment is to be discontinued, reduce the dosage gradually over a\\nperiod of 1 - 2 weeks \\n[see \\nWarnings and Precautions (\\n5.1\\n)\\n].\\n2.3 \\n  \\nMyocardial Infarction\\nSee prescribing information of intravenous metoprolol for dosage instructions for\\nintravenous therapy.\\nIn patients who tolerate the full intravenous dose, initiate Lopressor tablets, 50 mg every\\n6 hours, 15 minutes after the last intravenous dose of metoprolol and continue for\\n48 hours. In the case of intolerance, redu...","Lopressor\\nPlacebo\\nHypotension (systolic BP &lt; 90 mm\\nHg)\\n27.4%\\n23.2%\\nBradycardia (heart rate &lt;\\n40 beats/min)\\n15.9%\\n6.7%\\nSecond- or third-degree heart block\\n4.7%\\n4.7%\\nFirst-degree heart block (P-R \\u2265\\n0.26 sec)\\n5.3%\\n1.9%\\nHeart failure\\n27.5%\\n29.6%\\n6.2 \\n  \\nPost-Marketing Experience\\nThe following adverse reactions have been identified during post approval use of\\nLOPRESSOR. Because these reactions are reported voluntarily from a population of\\nuncertain size, it is not always possible to reliably estimate...","Product Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:30698-459\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nMETOPROLOL TARTRATE\\n (UNII: W5S57Y3A5L) \\n(METOPROLOL -\\nUNII:GEB06NHM23)\\nMETOPROLOL\\nTARTRATE\\n100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nFD&amp;C BLUE NO. 2\\n (UNII: L06K8R7DQK)\\n \\nLACTOSE, UNSPECIFIED FORM\\n (UNII: J...","LOPRESSOR- metoprolol tartrate tablet \\n \\nValidus Pharmaceuticals LLC\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use \\nLOPRESSOR\\n safely and\\neffectively. See full prescribing information for \\nLOPRESSOR\\n. \\n      \\n \\nLOPRESSOR\\n (metoprolol \\ntart\\nr\\nate\\n) \\nt\\nablet\\ns\\n,\\n for \\no\\nral \\nu\\nse\\n \\nInitial U.S. Approval: \\n1992\\n \\nINDICATIONS AND USAGE\\nLOPRESSOR is a beta-adrenergic blocker indicated for the treatment of:\\nHypertension, to lower blo...","dose of LOPRESSOR \\n[see \\nDosage and Administration (\\n2\\n)].\\n \\nIt may be necessary to lower\\nthe dose of LOPRESSOR or temporarily discontinue it. Such episodes do not preclude\\nsubsequent successful titration of LOPRESSOR.\\n5.3 \\n  \\nBronchospastic Disease\\nPatients with bronchospastic disease, should in general, not receive beta-blockers,\\nincluding Lopressor. Because of its relative beta\\n cardio-selectivity, however,\\nLOPRESSOR may be used in patients with bronchospastic disease who do not respond\\nto, o...","NDC 30698-458-01\\nLopressor\\n(metoprolol tartrate USP) Tablets\\n50 mg\\n100 Tablets\\nRx Only\\nPRINCIPAL DISPLAY PANEL\\nNDC 30698-459-01\\nLopressor\\n(metoprolol tartrate USP) Tablets\\n100 mg\\n100 Tablets\\nRx Only\\nLOPRESSOR  \\nmetoprolol tartrate tablet\\nProduct Information","CYP2D6 Inhibitors are likely to increase metoprolol concentration. (\\n7.3\\n)\\nConcomitant use of glycosides, clonidine, and diltiazem and verapamil with beta-blockers can increase\\nthe risk of bradycardia. (\\n7.4\\n)\\nBeta-blockers including metoprolol, may exacerbate the rebound hypertension that can follow the\\nwithdrawal of clonidine. (\\n7.4\\n)\\nUSE IN SPECIFIC POPULATIONS\\nHepatic Impairment: Consider initiating LOPRESSOR therapy at low doses and gradually increase\\ndosage to optimize therapy, while monit...","Validus Pharmaceuticals LLC\\n \\nRevised: 9/2023","Renal\\n \\nimpairment\\n: The systemic availability and half-life of Lopressor in patients with\\nrenal failure do not differ to a clinically significant degree from those in normal subjects.\\nHepatic Impairment:\\n Since the drug is primarily eliminated by hepatic metabolism,\\nhepatic impairment may impact the pharmacokinetics of metoprolol.\\nDrug Interactions\\nMetoprolol is metabolized predominantly by CYP2D6. In healthy subjects with CYP2D6\\nextensive metabolizer phenotype, coadministration of quinidine 10...","absolute risk increase per mmHg is greater at higher blood pressures, so that even\\nmodest reductions of severe hypertension can provide substantial benefit. Relative risk\\nreduction from blood pressure reduction is similar across populations with varying\\nabsolute risk, so the absolute benefit is greater in patients who are at higher risk\\nindependent of their hypertension (for example, patients with diabetes or\\nhyperlipidemia), and such patients would be expected to benefit from more aggressive\\ntr...","however, it is also reasonable to administer the drug orally to patients at a later time as\\nis recommended for certain other beta-blockers.\\n16 \\n     \\nHOW SUPPLIED/STORAGE AND HANDLING\\nLopressor \\n(\\nmetoprolol tartrate\\n)\\n \\nt\\nablets\\nTablets 50 mg \\n\\u2013 capsule-shaped, biconvex, pink, scored (imprinted LOPRESSOR on\\none side and 458 twice on the scored side)\\n      \\nBottles of 100\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026\\u2026.\\u2026\\u2026\\u2026NDC 30698-458-01\\nTablets 100 mg \\n\\u2013 capsule-shaped, biconvex, light blue, scored (imprinted LOPRESSOR\\non on...","Data\\nHuman Data\\nData from published observational studies did not demonstrate an association of major\\ncongenital malformations and use of metoprolol in pregnancy. The published literature\\nhas reported inconsistent findings of intrauterine growth retardation, preterm birth and\\nperinatal mortality with maternal use of metoprolol during pregnancy; however, these\\nstudies have methodological limitations hindering interpretation. Methodological\\nlimitations include retrospective design, concomitant use...","(range 17.0 to 158.7). The average relative infant dosage was 0.5% of the mother&#x27;s\\nweight-adjusted dosage.\\n8.\\n3 \\n \\nFemales and Males of Reproductive Potential\\nRisk Summary\\nBased on the published literature, beta-blockers (including metoprolol) may cause\\nerectile dysfunction and inhibit sperm motility. In animal fertility studies, metoprolol has\\nbeen associated with reversible adverse effects on spermatogenesis starting at oral\\ndose level of 3.5 mg/kg in rats, which would correspond to a dose of ...","5.\\n9\\n \\n  \\nPeripheral Vascular Disease\\nBeta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients\\nwith peripheral vascular disease.\\n6 \\n     \\nADVERSE REACTIONS\\nThe following adverse reactions are described elsewhere in labeling:\\nWorsening angina or myocardial infarction \\n[see \\nWarnings and Precautions (\\n5\\n)]\\n \\n \\nWorsening heart failure \\n[see \\nWarnings and Precautions (\\n5\\n)\\n]\\n.\\n \\nWorsening AV block \\n[see \\nContraindications (\\n4\\n)\\n]\\n.\\n6.1 \\n  \\nClinical Trials Experience\\n...","mg in a 60-kg patient.\\n14 \\n     \\nCLINICAL STUDIES\\n14.1 \\n  \\nHypertension\\nIn controlled clinical studies, Lopressor has been shown to be an effective\\nantihypertensive agent when used alone or as concomitant therapy with thiazide-type\\ndiuretics, at dosages of 100 mg to 450 mg daily. In controlled, comparative, clinical\\nstudies, Lopressor has been shown to be as effective an antihypertensive agent as\\npropranolol, methyldopa, and thiazide-type diuretics, to be equally effective in supine and\\nstanding...","and propafenone were shown to double metoprolol concentrations. While there is no\\ninformation about moderate or weak inhibitors, these too are likely to increase\\nmetoprolol concentration. Increases in plasma concentration decrease the\\ncardioselectivity of metoprolol \\n[see Clinical Pharmacology (\\n12.3\\n)]. \\nMonitor patients\\nclosely, when the combination cannot be avoided.\\n7.\\n4\\n \\n  \\nNegative Chronotropes\\nDigitalis glycosides, clonidine, diltiazem and verapamil slow atrioventricular conduction\\nand d...","Signs and Symptoms - Overdosage of LOPRESSOR may lead to severe bradycardia,\\nhypotension, and cardiogenic shock. Clinical presentation can also include:\\natrioventricular block, heart failure, bronchospasm, hypoxia, impairment of\\nconsciousness/coma, nausea and vomiting.\\nTreatment \\u2013 Consider treating the patient with intensive care. Patients with myocardial\\ninfarction or heart failure may be prone to significant hemodynamic instability. Beta-\\nblocker overdose may result in significant resistance t...","8.6 \\n  \\nHepatic Impairment\\n8.7 \\n  \\nRenal Impairment\\n10 \\n     \\nOVERDOSAGE\\n11 \\n     \\nDESCRIPTION\\n12 \\n      \\nCLINICAL PHARMACOLOGY\\n12.1 \\n   \\nMechanism of Action\\n12.2 \\n  \\nPharmacodynamics\\n12.3 \\n  \\nPharmacokinetics\\n12.5 \\n  \\nPharmacogenomics\\n13 \\n     \\nNONCLINICAL TOXICOLOGY\\n13.1 \\n  \\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\n14 \\n     \\nCLINICAL STUDIES\\n14.1 \\n  \\nHypertension\\n14.2 \\n  \\nAngina Pectoris\\n14.3 \\n  \\nMyocardial Infarction\\n16 \\n     \\nHOW SUPPLIED/STORAGE AND HANDLING\\n17 \\n     \\nPATIENT CO...","Metoprolol is a beta\\n-selective (cardioselective) adrenergic receptor blocking agent. This\\npreferential effect is not absolute, however, and at higher plasma concentrations,\\nmetoprolol also inhibits beta\\n-adrenoreceptors, chiefly located in the bronchial and\\nvascular musculature.\\nMetoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is\\ndetectable only at plasma concentrations much greater than required for beta-blockade.\\nAnimal and human experiments indicate tha...","the ratio of approximately 2.5:1.\\nThere is a linear relationship between the log of plasma levels and reduction of exercise\\nheart rate. \\nHowever, antihypertensive activity does not appear to be related to plasma\\nlevels. Because of variable plasma levels attained with a given dose and lack of a\\nconsistent relationship of antihypertensive activity to dose, selection of proper dosage\\nrequires individual titration.\\nIn several studies of patients with acute myocardial infarction, intravenous followed...","dose of LOPRESSOR \\n[see \\nDosage and Administration (\\n2\\n)].\\n \\nIt may be necessary to lower\\nthe dose of LOPRESSOR or temporarily discontinue it. Such episodes do not preclude\\nsubsequent successful titration of LOPRESSOR.\\n5.3 \\n  \\nBronchospastic Disease\\nPatients with bronchospastic disease, should in general, not receive beta-blockers,\\nincluding Lopressor. Because of its relative beta\\n cardio-selectivity, however,\\nLOPRESSOR may be used in patients with bronchospastic disease who do not respond\\nto, o...","the ratio of approximately 2.5:1.\\nThere is a linear relationship between the log of plasma levels and reduction of exercise\\nheart rate. \\nHowever, antihypertensive activity does not appear to be related to plasma\\nlevels. Because of variable plasma levels attained with a given dose and lack of a\\nconsistent relationship of antihypertensive activity to dose, selection of proper dosage\\nrequires individual titration.\\nIn several studies of patients with acute myocardial infarction, intravenous followed...","Lopressor\\nPlacebo\\nHypotension (systolic BP &lt; 90 mm\\nHg)\\n27.4%\\n23.2%\\nBradycardia (heart rate &lt;\\n40 beats/min)\\n15.9%\\n6.7%\\nSecond- or third-degree heart block\\n4.7%\\n4.7%\\nFirst-degree heart block (P-R \\u2265\\n0.26 sec)\\n5.3%\\n1.9%\\nHeart failure\\n27.5%\\n29.6%\\n6.2 \\n  \\nPost-Marketing Experience\\nThe following adverse reactions have been identified during post approval use of\\nLOPRESSOR. Because these reactions are reported voluntarily from a population of\\nuncertain size, it is not always possible to reliably estimate...","5.\\n9\\n \\n  \\nPeripheral Vascular Disease\\nBeta-blockers can precipitate or aggravate symptoms of arterial insufficiency in patients\\nwith peripheral vascular disease.\\n6 \\n     \\nADVERSE REACTIONS\\nThe following adverse reactions are described elsewhere in labeling:\\nWorsening angina or myocardial infarction \\n[see \\nWarnings and Precautions (\\n5\\n)]\\n \\n \\nWorsening heart failure \\n[see \\nWarnings and Precautions (\\n5\\n)\\n]\\n.\\n \\nWorsening AV block \\n[see \\nContraindications (\\n4\\n)\\n]\\n.\\n6.1 \\n  \\nClinical Trials Experience\\n..."]],["color",["#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#0a980a","#0a980a","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#0a980a","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#0a980a","#0a980a","#ba0e0e","#0a980a","#ba0e0e","#0a980a"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1339","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1340"}}},"glyph":{"type":"object","name":"Scatter","id":"p1335","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1336","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1337","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1353","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1344","attributes":{"selected":{"type":"object","name":"Selection","id":"p1345","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1346"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"Pdc5QHb4EUC3jVE/EWC6P2CwD0AYBkRAgf5xQK7fdEAC1FtAHepJQICeK0BBeB1Ae3H/P9TMrj8NXxdAvj/SP4El1j9nZjs/FzSBvuyh4z5GklE/"},"shape":[21],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"j05FQaCoTUH4f2FBZp5ZQavzWkG99lVBWR5bQTfyS0FnJm5BqXl8QRtrZ0HozThBLFaBQTCAeEF16XVByLtqQbuDQEEi+DxBN7JNQWWEU0HNrUlB"},"shape":[21],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1354","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1355"}}},"glyph":{"type":"object","name":"Scatter","id":"p1350","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1351","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1352","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1307","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p1322"},{"type":"object","name":"WheelZoomTool","id":"p1323","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1324","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1325","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1330"},{"type":"object","name":"SaveTool","id":"p1331"},{"type":"object","name":"HoverTool","id":"p1298","attributes":{"renderers":[{"id":"p1338"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1317","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1318","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1319"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1320"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1312","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1313","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1314"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1315"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1316","attributes":{"axis":{"id":"p1312"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1321","attributes":{"dimension":1,"axis":{"id":"p1317"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1341","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1342","attributes":{"label":{"type":"value","value":"False"},"renderers":[{"id":"p1338"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1343","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p1338"}],"index":4}}]}},{"type":"object","name":"LabelSet","id":"p1359","attributes":{"level":"glyph","source":{"type":"object","name":"ColumnDataSource","id":"p1356","attributes":{"selected":{"type":"object","name":"Selection","id":"p1357","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1358"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"2kEcQKqlHUA="},"shape":[2],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"2/VRQQO+eEE="},"shape":[2],"dtype":"float32","order":"little"}],["topic",["Metoprolol Medication","Metoprolol Pharmacology"]]]}}},"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"text":{"type":"field","field":"topic"},"text_color":{"type":"value","value":"#B1B1B1"},"text_font_size":{"type":"value","value":"12pt"},"text_font_style":{"type":"value","value":"bold"},"text_align":{"type":"value","value":"center"}}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"791622ef-16d6-4beb-9feb-a4de7dc4ff07","roots":{"p1364":"bad7df9d-1cba-4fdc-917b-7daa5e314a79"},"root_ids":["p1364"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="bad7df9d-1cba-4fdc-917b-7daa5e314a79" data-root-id="p1364" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
